ABSTRACT
OBJECTIVE: To evaluate the safety and epidemiological effect of the Freeze-dried Live attenuated varicella vaccine. METHODS: A random, double-blind control clinical trial was adopted. RESULTS: In the observation period, the incidence of varicella was 0.8 per thousand in the experimental group and 8.7 per thousand in control group. There was a significant difference (B.P=0.000017). Vaccine effectiveness (VE(%)) was 90.8%, the lower limit of 95%CI was 88.7%. CONCLUSION: The varicella vaccine produced by Changchun keygen biological products co., Ltd. was safe and effective.
Subject(s)
Chickenpox Vaccine/administration & dosage , Chickenpox/epidemiology , Chickenpox/prevention & control , Chickenpox/immunology , Chickenpox Vaccine/immunology , Child , Child, Preschool , China/epidemiology , Drug Evaluation, Preclinical , Female , Freeze Drying , Humans , Male , Vaccines, Attenuated/administration & dosage , Vaccines, Attenuated/immunologyABSTRACT
OBJECTIVE: To analysis the economic burden of varicella inpatient in China, 2007. METHODS: In three provinces, the sample places stratified by economic status in district, county and township level and were selected. 185 varicella inpatients were sampled and analysized. RESULTS: The cost of inpatient was 4025.86 RMB per case, including RMB 2952.6 direct cost and RMB 1073.26 indirect cost per case. The total cost of varicella inpatient in China was RMB 103 million in 2007. CONCLUSION: The disease burden is heavy in China.
